Echo IQ Highlights Market Potential for EchoSolv AS Following Presentation of New Data for Severe Aortic Stenosis (AS) Presented at AHA Scientific Sessions 2025
Echo IQ (OTC:ECHQF) highlighted two studies presented at AHA Scientific Sessions 2025 showing gaps in diagnosing and treating severe aortic stenosis (AS) and potential benefits of EchoSolv AS. A 30,878-echocardiogram investigator study found EchoSolv identified severe AS phenotypes more accurately than cardiologists and improved the male:female diagnosis ratio from 2.2:1 to 1.1:1. A separate real-world analysis of 1.18 million echocardiograms from NEDA linked to national health data found only 36% of women and 45% of men with moderate-to-severe AS received intervention and that “watchful waiting” was associated with substantial life-years lost. EchoSolv AS has FDA clearance and is positioned as a decision-support tool to reduce diagnostic delays and improve intervention timing.
Echo IQ (OTC:ECHQF) ha evidenziato due studi presentati alle AHA Scientific Sessions 2025 che mostrano lacune nella diagnostica e nel trattamento della stenosi aortica severa (AS) e i potenziali benefici di EchoSolv AS. Uno studio investigativo su 30.878 ecocardiogrammi ha rilevato che EchoSolv identificava i fenotipi di AS severa in modo più accurato rispetto ai cardiologi e migliorava il rapporto di diagnosi maschio:femmina da 2.2:1 a 1.1:1. Un'analisi separata del mondo reale su 1,18 milioni di ecocardiogrammi da NEDA collegati ai dati sanitari nazionali ha rilevato che solo 36% delle donne e 45% degli uomini con AS moderata-severa hanno ricevuto un intervento e che il watchful waiting era associato a una sostanziale perdita di anni di vita. EchoSolv AS ha l'approvazione FDA ed è posizionato come strumento di supporto alle decisioni per ridurre i ritardi diagnostici e migliorare i tempi di intervento.
Echo IQ (OTC:ECHQF) destacó dos estudios presentados en las AHA Scientific Sessions 2025 que muestran brechas en el diagnóstico y tratamiento de la estenosis aórtica severa (AS) y los posibles beneficios de EchoSolv AS. Un estudio investigador de 30.878 ecocardiogramas encontró que EchoSolv identificó fenotipos de AS severa con mayor precisión que los cardiólogos y mejoró la relación de diagnóstico hombre:mujer de 2.2:1 a 1.1:1. Un análisis real-world de 1.18 millones de ecocardiogramas de NEDA vinculados a datos de salud nacionales encontró que solo 36% de las mujeres y 45% de los hombres con AS moderada-severa recibieron intervención y que la vigilancia vigilante (watchful waiting) se asoció con pérdidas sustanciales de años de vida. EchoSolv AS tiene aprobación de la FDA y se posiciona como una herramienta de apoyo a la decisión para reducir retrasos en el diagnóstico y mejorar el momento de la intervención.
Echo IQ (OTC:ECHQF)는 AHA Scientific Sessions 2025에서 중등도-중증의 대동맥판 협착증(AS) 진단 및 치료의 격차와 EchoSolv AS의 잠재적 이점을 보여주는 두 가지 연구를 강조했습니다. 30,878건의 심초음파 연구자 연구에서 EchoSolv가 심장 전문의보다 AS 중증 표현형을 더 정확하게 식별했고 남성-여성 진단 비율을 2.2:1에서 1.1:1로개선했습니다. NEDA의 118만 개의 심초음파를 건강 데이터와 연계한 실세계 분석은 중등도~중증 AS를 가진 여성의 36%, 남성의 45%만이 개입을 받았고, watchful waiting(감시 대기)이 상당한 생년수 손실과 연관이 있음을 밝혔습니다. EchoSolv AS는 FDA 승인을 받았으며 진단 지연을 줄이고 개입 시점을 개선하기 위한 의사결정 지원 도구로 자리매김하고 있습니다.
Echo IQ (OTC:ECHQF) a mis en évidence deux études présentées lors des AHA Scientific Sessions 2025 montrant des lacunes dans le diagnostic et le traitement de la sténose aortique sévère (AS) et les bénéfices potentiels d'EchoSolv AS. Une étude d'investigation sur 30 878 échocardiographies a montré qu'EchoSolv identifiait les phénotypes d'AS sévère avec une précision accrue par rapport aux cardiologues et améliorait le ratio diagnostic homme:femme de 2,2:1 à 1,1:1. Une autre analyse en vrai monde de 1,18 million d'échocardiographies issues de NEDA reliées à des données de santé nationales a démontré que seulement 36% des femmes et 45% des hommes atteints d'AS modérée-sevère recevaient une intervention et que la « watchful waiting » était associée à une perte substantielle d'années de vie. EchoSolv AS possède l'approbation FDA et est positionné comme un outil d'aide à la décision pour réduire les retards de diagnostic et améliorer le moment de l'intervention.
Echo IQ (OTC:ECHQF) hob zwei Studien hervorgehoben, die auf den AHA Scientific Sessions 2025 präsentiert wurden und Lücken bei der Diagnose und Behandlung einer schweren Aortenklappenstenose (AS) sowie potenzielle Vorteile von EchoSolv AS aufzeigen. Eine Investigator-Studie mit 30.878 Echokardiogrammen ergab, dass EchoSolv schwere AS-Phänotypen genauer identifizierte als Kardiologen und das Geschlechter-Diagnoseverhältnis von 2,2:1 auf 1,1:1 verbesserte. Eine separate Real-World-Analyse von 1,18 Millionen Echokardiogrammen aus NEDA, verknüpft mit nationalen Gesundheitsdaten, zeigte, dass nur 36% der Frauen und 45% der Männer mit moderat-schwerer AS eine Intervention erhielten und dass „watchful waiting“ mit deutlichen Lebensjahresverlusten verbunden war. EchoSolv AS hat die FDA-Zulassung und positioniert sich als Entscheidungsunterstützungstool, um diagnostische Verzögerungen zu reduzieren und den Interventionszeitpunkt zu verbessern.
Echo IQ (OTC:ECHQF) أبرز دراستين قدمتا في جلسة AHA Scientific Sessions 2025 تُظهران ثغرات في تشخيص وعلاج تضيق الأبهر الحاد (AS) والفوائد المحتملة لـ EchoSolv AS. وجدت دراسة استقصائية شملت 30,878 فحصًا بالموجات فوق الصوتية أن EchoSolv حدد فيروسات AS الشديدة بدقة أعلى من أطباء القلب وحسن نسبة التشخيص للذكور مقابل الإناث من 2.2:1 إلى 1.1:1. وأظهر تحليل واقعي منفصل من 1.18 مليون فحص بالموجات فوق الصوتية من NEDA مرتبط ببيانات صحية وطنية أن فقط 36% من النساء و45% من الرجال المصابين بـ AS المتوسط إلى الشديد تلقوا تدخلاً وأن عمر الحياة قد فُقد بشكل كبير مع ما يسمى بالمراقبة اليقظة. EchoSolv AS حاصل على موافقة FDA ويُوجّه كأداة دعم لاتخاذ القرار من أجل تقليل التأخيرات في التشخيص وتحسين توقيت التدخل.
- EchoSolv outperformed cardiologists in 30,878 echocardiograms
- Diagnosis gender ratio improved from 2.2:1 to 1.1:1
- NEDA analysis covered 1.18 million patients (2010–2021)
- EchoSolv AS has received FDA clearance
- Only 36% of women with moderate-to-severe AS received intervention
- Only 45% of men with moderate-to-severe AS received intervention
- ‘Watchful waiting’ linked to substantial life-years lost
- Investigator-initiated study shows potential for EchoSolv AS to drive improved patient outcomes when used to support cardiologist in identifying severe AS particularly in women
- NEDA study of 1.2M patients’ echocardiograms reveals gap in standard-of-care for severe AS; highlighting significant medical need for improved monitoring and diagnosis
SYDNEY, Nov. 12, 2025 (GLOBE NEWSWIRE) -- AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ) today announced that overwhelmingly convincing data from two recent studies have highlighted the significant gaps in the current standard-of-care for diagnosing and monitoring severe aortic stenosis (AS), and potential for EchoSolv AS to drive improved patient outcomes. The results from both studies were presented separately at the American Heart Association (AHA) Scientific Sessions 2025, which was held in New Orleans, Louisiana.
Chief Executive Officer, Mr Dustin Haines said: “The cumulative data from the two severe AS studies presented by the University of Notre Dame Australia Researchers at AHA25 have reinforced our commitment to leveraging advanced analytics and AI to transform severe AS care for patients. A key takeaway from the study that reviewed echocardiograms for more than 1.2 million patients is that the ‘watchful waiting’ strategy for moderate-to-severe AS cases is failing many of these patients. In addition, we are excited by the insights from the results that show how EchoSolv AS was able to identify the severe AS phenotype more accurately than cardiologists, particularly in some subtypes of AS. This study was of particular interest as it showed clearly that we have work to do in accurately diagnosing women with aortic stenosis and we are optimistic with the performance of EchoSolv AS to improve the gender equity.”
Study titled, “Accuracy of cardiologist reporting of severe aortic stenosis vs decision-support artificial intelligence and its impact on clinical management”
Presented by Dr. Vikas Bhat, University of Notre Dame Australia, this investigator-initiated study compared traditional cardiologist reporting with EchoSolv™, an AI-powered clinical decision support system. Findings from 30,878 echocardiograms revealed:
- EchoSolv outperformed cardiologists in identifying severe AS phenotypes, particularly in women and low-gradient cases.
- EchoSolv-driven reporting restored gender equity in diagnosis, with male to female ratio improved from 2.2:1 to 1.1:1.
- Adoption of real-time EchoSolv support could reduce delays in diagnosis and valve intervention, improving patient outcomes.
Echo Report Influences Follow-up and Management
n=774 meeting severe AS guidelines
Only patients REPORTED severe were considered for valve intervention
This study is an investigator-initiated study and received no external funding.
Study titled, “Hemodynamic profile of Aortic Stenosis versus health service delivery from 1,200,000 individuals”
Presented by Professor Geoff Strange, Professor of Medicine at The University of Notre Dame Australia, this real-world included the analysis of 1.18 million subjects aged at least 18 years and undergoing echocardiography during the period of 2010 - 2021 for repeat or investigation of cardiovascular disease. These data were pulled from 45 centres in Australia that contribute to the National Echo Database of Australia (NEDA), and individuals were then linked to the Australian Institute of Health and Welfare’s (AIHW’s), National Health Data Hub (NHDH). The study suggests:
- A significant discordance between haemodynamic severity and treatment rates – only
36% of women and45% of men with moderate-to-severe AS received intervention. - “Watchful waiting” strategy linked to substantial life-years lost compared to timely aortic valve replacement (AVR).
- Findings underscore the need for policy and clinical practice changes to address treatment gaps and improve survival.
This study was funded by an IIS grant from Edwards LifeScience. The funders played no part in the data curation / analysis / preparation of these data.
EchoSolv AS is poised to change this paradigm by enabling more precise and consistent identification of high-risk AS patients, thereby supporting clinicians in making informed, timely decisions regarding intervention. Globally, AS is a widespread but frequently underdiagnosed condition, primarily caused by calcification of the aortic valve, which serves as a critical gateway to the heart. Failure to diagnose AS in a timely manner can lead to missed opportunities for lifesaving interventions, such as valve replacement surgery. EchoSolv AS has undergone rigorous validation, including FDA Clearance, through extensive testing across both the United States and Australia, demonstrating the utility of aiding in the accurate diagnosis of patients with aortic stenosis.
NEDA principal investigator, Professor David Playford, the senior author for both studies, said: “These studies confirm previous reports in two ways. First, we reaffirm that moderate and severe aortic stenosis is a life threatening condition that causes significant health service utilization, heart failure hospitalizations and premature mortality. Second, artificial intelligence is capable of outperforming cardiologists in the identification of the set of abnormalities that happen when aortic stenosis progresses toward the severe state. These two findings, taken together, reinforce that EchoSolv AS AI should be considered as a routine option during echocardiographic reporting.
Authorised for release by the Board of Directors of Echo IQ Limited.
| Investor Enquiries: | |
| Andrew Grover, Executive Chair | Henry Jordan, Six Degrees Investor Relations |
| Andrew.grover@echoiq.ai / investor@echoiq.ai | Henry.jordan@sdir.com.au / +61 (0) 431 271 538 |
ABOUT ECHO IQ
Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology.
The company is based in Sydney, Australia.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/2edccc84-6a52-409f-a130-b402f1f62f43
https://www.globenewswire.com/NewsRoom/AttachmentNg/cb55c68a-d320-456b-a219-7e11b54dc98d
FAQ
What did Echo IQ announce about EchoSolv AS on November 12, 2025 (ECHQF)?
How many echocardiograms were analyzed in the NEDA real-world study cited by Echo IQ (ECHQF)?
What diagnostic improvement did EchoSolv AS achieve versus cardiologists in the 30,878-case study?
What treatment-rate gaps did Echo IQ report that could affect ECHQF investors?
Does EchoSolv AS have regulatory clearance relevant to commercialization (ECHQF)?
How might EchoSolv AS affect patient care timelines if adopted broadly (ECHQF)?
